Fig. 7: Rapamycin treatment ameliorates MYTHO knockdown (MYTHO-KD) induced myopathy.
From: MYTHO is a novel regulator of skeletal muscle autophagy and integrity
A Schematic representation of the experimental design. B Immunoblot detection and quantification of MYTHO in TA muscles from mice treated for 3 weeks with rapamycin (Rap) or vehicle at 3 weeks post AAV-mediated transduction. C Quantification of Mytho mRNA expression in muscle assessed by RT-qPCR. Data were normalized by the geometric mean of 18 S, β-Actin, and Cyclophilin. D Immunoblots detection and quantification of pS6 and total S6 in TA muscles demonstrating mTORC1 inhibition in mice treated with rapamycin. E TA muscle mass from mice treated with vehicle or rapamycin 6 weeks post AAV-mediated transduction. F in situ assessment of muscle-specific force in AAV sh-RNA scramble and AAV sh-RNA MYTHO injected TA muscles from mice treated with vehicle or rapamycin. G Representative H&E staining, H corresponding analysis of muscle fiber diameter and I proportion of fibers with centralized nuclei in AAV sh-RNA scramble and AAV sh-RNA MYTHO TA muscles from mice treated for 3 weeks with rapamycin or vehicle at 3 weeks post AAV-mediated transduction. Large scale bars = 200 µm, inset scale bar = 100 µm. The number of mice for each group is indicated within bars. Data in B–F, H, I were analyzed with two-way ANOVA, and corrections for multiple comparisons were performed with the two-stage step-up method of Benjamini, Krieger, and Yekutieli (∗p < 0.05 and q < 0.1). Data are presented as mean ± SEM (with individual data points). Detailed information on raw data, statistical tests, p values, and q values are provided in the Source Data file. A was created with BioRender.com.
